Agios’ first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disorder esagonowsky Thu, 02/17/2022 – 16:45 More: Agios' first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disorder Source: fierce
read moreOrganon CEO pins high hopes on upcoming Humira biosimilar launch fkansteiner Thu, 02/17/2022 – 13:05 More: Organon CEO pins high hopes on upcoming Humira biosimilar launch Source: fierce
read moreASCO GU: Bayer tees up another 3-way battle against Pfizer-Astellas, J&J with new Nubeqa prostate cancer data aliu Thu, 02/17/2022 – 12:22 More: ASCO GU: Bayer tees up another 3-way battle against Pfizer-Astellas, J&J with new Nubeqa prostate cancer data
read moreGSK launches trade secrets case against former employee, ordering data and property to be returned ‘in one piece’ fkansteiner Thu, 02/17/2022 – 11:02 More: GSK launches trade secrets case against former employee, ordering data and property to be returned 'in
read moreTeva takes ‘skinny’ label dispute with GlaxoSmithKline to the Supreme Court: reports fkansteiner Thu, 02/17/2022 – 09:40 More: Teva takes 'skinny' label dispute with GlaxoSmithKline to the Supreme Court: reports Source: fierce
read moreFirst direct-to-PCR test added to the CTDA register of approved UK products More: Seal of Approval: Direct-to-PCR COVID-19 test in the UK validated Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals